Co-sponsored by the:
U.S. Food & Drug Administration (FDA) and the International Association for the Study of Lung Cancer (IASLC)
Date: March 1-2, 2018
Time: Thursday, March 1, 3:30 – 7:30pm, Friday, March 2, 7:30am – 4:00pm
Location: Marriott Bethesda North Hotel and Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852
The Food and Drug Administration (FDA), and the IASLC have expressed a willingness to leverage their combined strengths for the joint development of the substantive actions of this workshop to focus on providing a forum to discuss relevant scientific advances in the field of neoadjuvant therapies in NSCLC and the regulatory environment that will support rapid translation of these treatment modalities into improved patient care.
Goals and Objectives:
- To provide a forum for open discussion within the scientific community,
- To seek feedback from industry, academia, and other stakeholders on development of cures for neoadjuvant non-small cell lung cancer,
- To enhance communication with other stakeholders such as Trade Associations, manufacturers, payers, and health care systems regarding neoadjuvant therapy in NSCLC,
- To help incorporate emerging scientific findings into regulatory policies.
Who Should Attend:
The primary audience includes leading academic and clinical scientists involved in drug development, regulatory government agencies in the US and abroad. It is anticipated that a total of 100 - 200 people will attend this workshop.
Pia Hirsch: Pia.Hirsch@iaslc.org
Jura Viesulas: Jura.Viesulas@fda.hhs.gov